tickdelta
Sign in
Screener / SEC EDGAR /CIK 0000313616 /10-K filed Feb 24, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
BDXGILDGEHCUHSDHRBSX
NYSE Health care · Industrial Instruments

Danaher Corporation DHR

DHR quote by TradingView

Danaher is a global science and technology innovator committed to accelerating the power of science and technology to improve human health. 10-K, Item 1

Employees
60,000
Headquarters
Washington, DC
CEO
Rainer Blair
Next results
around Jan 11, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $24.6B through the costs to a net profit of $3.6B · income statement of the 10-K

19% operating margin
Revenue to Gross profit: $14.5BRevenue to Cost of revenue: $10.0BGross profit to Operating profit: $4.7BGross profit to Operating expenses: $9.8BOperating profit to Net profit: $3.6BOperating profit to Tax & other: $1.1BOperating expenses to R&D: $1.6BOperating expenses to SG&A: $8.2B Revenue: $24.6B REVENUE $24.6B +3% Y/Y Gross profit: $14.5B · 59% margin GROSS PROFIT $14.5B 59% margin · +2% Y/Y Cost of revenue: $10.0B · 41% of revenue COST OF REVENUE $10.0B 41% of revenue Operating profit: $4.7B · 19% margin OPERATING PROFIT $4.7B 19% margin · −4% Y/Y Operating expenses: $9.8B · 40% of revenue OPERATING EXPENSES $9.8B 40% of revenue Net profit: $3.6B · 15% margin NET PROFIT $3.6B 15% margin · −7% Y/Y Tax & other: $1.1B · 4% of revenue TAX & OTHER $1.1B 4% of revenue R&D: $1.6B · 7% of revenue R&D $1.6B 7% of revenue SG&A: $8.2B · 34% of revenue SG&A $8.2B 34% of revenue
Gross profit $14.5B 59% margin · +2% Y/Y
Operating profit $4.7B 19% margin · −4% Y/Y
Net profit $3.6B 15% margin · −7% Y/Y
The full income statement, year by year

DHR among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.

Compare
Revenue growth: 2.9%, above 24% of 59 peers (their median 7.2%) REVENUE GROWTH 2.9% · above 24% Gross margin: 58.6%, above 38% of 50 peers (their median 65.2%) GROSS MARGIN 58.6% · above 38% Operating margin: 20.4%, above 72% of 50 peers (their median 13.4%) OPERATING MARGIN 20.4% · above 72% Net margin: 16.9%, above 75% of 59 peers (their median 9.5%) NET MARGIN 16.9% · above 75% FCF margin: 22.4%, above 80% of 55 peers (their median 15.2%) FCF MARGIN 22.4% · above 80% Return on capital: 4.9%, above 12% of 41 peers (their median 9.2%) RETURN ON CAPITAL 4.9% · above 12%
DHR Peer median Below the median

What changed

6 new risk paragraphs. 10-K filed Feb 24, 2026 against Feb 20, 2025.

Risk factors
6 new paragraphs, nothing like them in the previous 10-K
10-K Item 1A
Accounting checks
11 other checks clear
10-K · XBRL
Insiders
No open-market buys in the last 90 days
Form 4
Filings
8 in the last 30 days
EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 11 checks found nothing to note

  • Receivables +10.6% vs revenue +2.9% (+7.7 pts)
  • Cash from operations $6.4B vs net income $3.6B (FY ending Dec 31, 2025)
  • Inventory +6.8% vs revenue +2.9% (+3.9 pts)
8 more checks with nothing to note
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Uncertain Tax Positions
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

6 paragraphs in Risk Factors that were not in the 10-K filed Feb 20, 2025. Quoted as filed.

All 6 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    Our ability to grow revenues, earnings and cash flow at or above our historic rates depends in part upon our ability to identify and successfully acquire and integrate businesses at appropriate prices and realize anticipated synergies, and to make appropriate investments that support our long-term strategy. Over the past several years…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    We rely on IT systems, some of which are provided and/or managed by third-parties, to collect, use, store, transfer and otherwise process electronic information (including sensitive data such as confidential business information and personal
  3. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    In addition, any businesses or technologies that we acquire may exacerbate the risks set forth above, for example due to acquired vulnerabilities or threats that were unknown or were ineffectively managed.
  4. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    In addition, a significant number of countries where we operate have enacted privacy or data protection laws, rules and regulations, many of which have extraterritorial scope, with significant penalties for non-compliance. For example, failure to comply with the requirements of the GDPR and the applicable national data protection laws…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$26.6B$23.9B$23.9B$24.6B
Net income$7.2B$4.8B$3.9B$3.6B
Operating cash flow$8.5B$7.2B$6.7B$6.4B
Free cash flow$7.4B$5.8B$5.3B$5.3B

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$24.6B ▲ 2.9% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

8 filings in the last 30 days · SEC EDGAR

All filings
3 more

About the company

Danaher Corporation, Washington, DC · from the 10-K filed Feb 24, 2026

Danaher is a global science and technology innovator committed to accelerating the power of science and technology to improve human health. Danaher is comprised of more than 15 operating companies with leadership positions in the biotechnology, life sciences and diagnostics sectors, organized under three segments (Biotechnology, Life Sciences and Diagnostics). United by the DANAHER BUSINESS SYSTEM (“DBS”), our businesses are also typically characterized by a high level of products and services that are sold on a recurring basis, primarily through a direct sales model and to a geographically diverse customer base.

Headquarters
Washington, DC
Country
United States
Reports in
USD
Listed on
NYSE
Fiscal year ends
December 31
Last results
Oct 21, 2026
Incorporated in
DE

Employees, at the top of the page: "As of December 31, 2025, the Company had approximately 60,000 employees (whom we refer to as “associates”), of whom approximately 22,000 were employed in North America, 20,000 in Western Europe, 3,000 in other developed markets and 15,000 in high-growth markets" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 24, 2026 (open at SEC), compared with the 10-K filed Feb 20, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/DHR/export.csv") into a cell.